

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lau et al

Application No.: To Be Assigned

Group Art Unit: To be assigned

Filed: November 13, 2003

Examiner: To be assigned

For: Glucagon Antagonists/Inverse Agonists

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. **Copies of all references were either submitted to, or cited by, the Patent Office in parent application USSN 09/996,023 filed on November 16, 2001.**

The references are as follows:

1. WO 00/39088
2. WO 94/14426
3. WO 98/04528
4. WO 98/21957

5. WO 98/22108
6. WO 98/22109
7. WO 99/01423
8. WO 97/16442
9. WO 98/24780
10. WO 98/24782
11. WO 99/24404
12. WO 99/32448
13. WO 00/69810
14. US 5,880,139
15. US 5,776,954
16. US 4,359,474
17. US 4,374,130
18. US 5,837,719
19. US 6,503,949
20. C.L. Brand et al., "Immunoneutralization of endogenous glucagons with monoclonal glucagons antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats" *Diabetologia* Vol. 37 pgs. 985-993 (1994)
21. C.L. Brand et al., "Evidence for a Major Role of Glucagon in the Hyperglycemia of Experimental Diabetes" [535] *Diabetes* 43, [suppl 1], 172A (1994)
22. C. L. Brand et al., *Am. J. Physiol.* 269, E469-E477 (1995)
23. C.L. Brand et al., "Regulation of Insulin and Glucagon Secretion by Glucagon" [492], *Diabetes* 44 [suppl 1], 134A (1995)
24. C.L. Brand et al., "Evidence for a Major Role for Glucagon in Regulation of Plasma Glucose in Conscious, Nondiabetic, and Alloxan-Induced Diabetic Rabbits", *Diabetes* Vol. 45., pages. 1076-1083 (1996)
25. L.J.Jelinek et al., "Expression Cloning and Signaling Properties of the Rat Glucagon Receptor" *Science* Vol. 259., pages. 1614-1616 (1993)
26. J.L. Collins et al., "CP-99, 711: A NON-PEPTIDE GLUCAGON RECEPTOR ANTAGONIST" *Bioorganic & Med. Chem. Ltr.* Vol. 2, No. 9 pages. 915-918 (1992)
27. P. Madsen et al., "Discovery and Structure-Activity Relationship of the First Non-Peptide Competitive Human Glucagon Receptor Antagonists" *J. Med. Chem* Vol. 41, pages. 5150-5157 (1998)


It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

Attorney Docket No.: 6258.210-US
Express Mail Label No.: EV 246877038 US

The information disclosure statement submitted herewith is being filed **before** the mailing date of a first Office action on the merits. Therefore, no fee is due.

Respectfully submitted,

Date: November 13, 2003


Richard W. Bork, Reg. No. 36,459
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

23650

PATENT TRADEMARK OFFICE

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEAtty. Docket No. **6258.210-US**Serial No. **To Be Assigned**INFORMATION DISCLOSURE
STATEMENT BY APPLICANTApplicant **Lau et al**

(Use several sheets if necessary)

Filing Date **November 13, 2003**Group **To Be Assigned**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,880,139	03/09/99	L.L. Chang	514	326	11/17/97
	5,776,954	07/07/98	de Laszlo et al	514	340	10/30/96
	4,359,474	11/16/82	Anderson et al	424	273	11/28/80
	4,374,130	02/15/83	Barcza	424	184	02/15/83
	5,837,719	11/17/98	de Laszlo et al	514	343	08/08/96
	6,503,949	01/2003	Lau et al.	514	617	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 00/39088	06/07/00	WIPO				
	WO 94/14426	07/07/94	WIPO				
	WO 98/04528	05/02/98	WIPO				
	WO 98/21957	28/05/98	WIPO				
	WO 00/69810	23/11/00	WIPO			X	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C.L. Brand et al., "Immunoneutralization of endogenous glucagons with Monoclonal glucagons antibody normalizes hyperglycaemia in moderately Streptozotocin-diabetic rats" <i>Diabetologia</i> , Vol. 37 pgs.985-993 (1994)
	C.L. Brand et al [535] <i>Diabetes</i> 43, [suppl 1], 172A (1994)
	C.L. Brand et al., <i>Am J. Physiol.</i> 269, E469-E477 (1995)
	C.L. Brand et al [492] <i>Diabetes</i> 44 [suppl 1], 134A (1995)
	C.L. Brand et al., "Evidence for a Major Role for Glucagon in Regulation of Plasma Glucose in Conscious, Nondiabetic, and Alloxan Induced Diabetic Rabbits", <i>Diabetes</i> Vol. 45, pgs. 1076-1083 (1996)
	L.J. Jelinek et al., "Expression Cloning and Signaling Properties of the Rat Glucagon Receptor" <i>Science</i> Vol. 259, pgs. 1614-1616 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEAtty. Docket No. **6258.210-US**Serial No. **To Be Assigned**INFORMATION DISCLOSURE
STATEMENT BY APPLICANTApplicant
Lau et al

(Use several sheets if necessary)

Filing Date **November 13, 2003**Group **To Be Assigned**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 98/22108	28/05/98	WIPO				
	WO 98/22109	28/05/98	WIPO				
	WO 99/01423	14/01/99	WIPO				
	WO 98/24780	09/05/97	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	J.L. Collins et al., "CP-99, 711: A Non-Peptide Glucagon Receptor
	Antagonist" Bioorganic & Med.Chem.Ltr. Vol.2, No. 9, pgs. 915-918
	(1992)
	P. Madsen et al., "Discovery and Structure-Activity Relationship
	Of the First Non-Peptide Competitive Human Glucagon Receptor
	Antagonists" J.Med.Chem. Vo. 41, pages. 5150-5157 (1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEAtty. Docket No. **6258.210-US**Serial No. **To Be Assigned**INFORMATION DISCLOSURE
STATEMENT BY APPLICANTApplicant **Lau et al**

(Use several sheets if necessary)

Filing Date **November 13, 2003**Group **To Be Assigned**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 98/24782	11/06/98	WIPO				
		WO 99/24404	20/05/99	WIPO				
		WO 99/32448	01/07/99	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.